A lawsuit alleged that Global Pharmaceuticals and Impax Laboratories Inc. falsely advertised and marketed their products as generic equivalents to and substitutes for Solvay Pharmaceuticals Inc.'s drugs to treat pancreatic exocrine insufficiency. The two companies have agreed to pay Solvay Pharmaceuticals Inc. $23 million to settle-Solvay reports that $12 million has already been paid. As well, Global and Impax also must discontinue marketing that states or implies its products are generic equivalents to Solvay's Creon brand products. Creon is used to treat pancreatic exocrine insufficiency, which is often associated with conditions such as cystic fibrosis and chronic pancreatitis. (Jul-10-06)[]
http://www.lawyersandsettlements.com/
